NASDAQ:SBOT Stellar Biotechnologies (SBOT) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free SBOT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.75▼$3.2850-Day Range$4.44▼$298,098.0052-Week Range$0.75▼$3.25Volume472,272 shsAverage Volume2.95 million shsMarket Capitalization$15.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Stellar Biotechnologies alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Stellar Biotechnologies Stock (NASDAQ:SBOT)Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.Read More Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. SBOT Stock News HeadlinesApril 18, 2024 | techcrunch.comUber, Nvidia-backed Serve Robotics hits public markets with $40M splashJuly 30, 2023 | nypost.comZach Wilson’s stellar day at Jets camp includes long touchdown throwApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.June 7, 2023 | forbes.comCaterpillar's Stellar Move To Attract High-Quality EmployeesFebruary 26, 2023 | benzinga.comStellar Bancorp, Inc. Declares Quarterly DividendOctober 5, 2022 | cbsnews.comO's closer Felix Bautista goes on DL ending stellar rookie yearSee More Headlines Receive SBOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stellar Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2019Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SBOT CUSIPN/A CIK1540159 Webwww.stellarbiotechnologies.com Phone805-488-2800FaxN/AEmployees25Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,030,000.00 Net Margins-1,782.64% Pretax MarginN/A Return on Equity-51.12% Return on Assets-48.37% Debt Debt-to-Equity RatioN/A Current Ratio9.24 Quick Ratio8.96 Sales & Book Value Annual Sales$210,000.00 Price / Sales71.57 Cash FlowN/A Price / Cash FlowN/A Book Value$2.12 per share Price / Book1.33Miscellaneous Outstanding Shares5,330,000Free FloatN/AMarket Cap$15.03 million OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Frank R. Oakes (Age 69)Chairman, Pres & CEO Ms. Kathi Niffenegger CPA (Age 62)CFO & Corp. Sec. Mr. Gary KoppenjanSr. Director of Investor Relations & CommunicationsBrando LincicumExec. Director of Aquaculture and Facility OperationsKey CompetitorsVBI VaccinesNASDAQ:VBIVMinerva NeurosciencesNASDAQ:NERVTalpheraNASDAQ:TLPHBenitec BiopharmaNASDAQ:BNTCOrgenesisNASDAQ:ORGSView All Competitors SBOT Stock Analysis - Frequently Asked Questions How were Stellar Biotechnologies' earnings last quarter? Stellar Biotechnologies Inc (NASDAQ:SBOT) announced its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.05. The biotechnology company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.11 million. Stellar Biotechnologies had a negative net margin of 1,782.64% and a negative trailing twelve-month return on equity of 51.12%. When did Stellar Biotechnologies' stock split? Shares of Stellar Biotechnologies reverse split before market open on Monday, May 7th 2018. The 1-7 reverse split was announced on Friday, April 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 4th 2018. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of Stellar Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stellar Biotechnologies investors own include Heat Biologics (HTBX), XOMA (XOMA), Anavex Life Sciences (AVXL), EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Statoil ASA (STO), Abraxas Petroleum (AXAS) and Carrizo Oil & Gas (CRZO). This page (NASDAQ:SBOT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWall Street Legend Issues New NVDA WarningChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stellar Biotechnologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
